This paper examines the ethical considerations that govern clinical testing, with a focus on research involving patients with Obstructive Sleep Apnea (OSA) in the United States. Drawing on established regulatory frameworks such as the Declaration of Helsinki, the paper outlines core requirements for ethical clinical trials: informed consent, protection of vulnerable subjects, voluntary and just subject selection, a favorable risk-benefit ratio, and the use of qualified investigators. The paper also evaluates the strengths and limitations of a key article by Brown et al. (2011), highlighting its treatment of resource-limited environments and identifying a gap in its discussion of patient privacy and confidentiality.
The conduct of medical professionals during their course of duty is regulated and governed by established rules relating to their profession. The basis of these regulations is primarily to safeguard the rights of patients. Patients must be accorded the utmost respect and handled in a dignified manner. Regulations also cover what equipment may be used in an operation, the conditions of treatment facilities such as hospitals, and standards of hygiene. This paper focuses on the ethical issues that surround the observation of patients with Obstructive Sleep Apnea (OSA) in the United States — a condition in which a patient experiences breathing difficulties during sleep that are typically undetected by the patient and can only be observed by those sleeping nearby. The paper also identifies ethical considerations that were absent from the reviewed literature but remain critically important.
For a clinical test to be considered ethical, it must meet several basic requirements. These include proper sourcing of consent from the party receiving the test, appropriate treatment of controlled subjects such as children, and just and voluntary subject selection. Additional requirements include the use of qualified investigators, demonstrated scientific value, and independent review. Each of these requirements holds a central position in an ethical testing framework (Silverman, 2007).
The Declaration of Helsinki provides a foundational reference point for many of these requirements, setting internationally recognized ethical principles for medical research involving human subjects. Adherence to this declaration helps ensure that investigators operate within accepted moral and legal boundaries.
Before any test is performed on a patient, consent must be duly obtained. The consent must clearly express the subject's desire and willingness to undergo the test. It must also inform the patient of any dangers and risks likely to be encountered. In this regard, consent becomes a binding agreement between the investigator and the subject: the investigator is bound to conduct the test to the best of their ability, and the subject agrees to cooperate and accept the results.
For enrolled subjects such as prisoners, fetuses, or children, the situation is more complex. Nevertheless, these individuals must be accorded due consideration, as protection is their right. Given their inherent vulnerability, specific rules and regulations bind and regulate the investigator in such cases. There is also a requirement that investigators work with at least one colleague when dealing with these enrolled subjects. It is widely understood that without such protections, vulnerable subjects can easily have their rights violated by ill-intentioned investigators (Brown et al., 2011).
The selection of subjects to be investigated must be just and voluntary. No one should be coerced into accepting an OSA investigation. Willingness and voluntarism are demonstrated through a freely written expression of interest and a subsequent submission of a signed consent form. It is equally important that no investigation be conducted on individuals who object to undergoing it. This is addressed by the requirement of a favorable risk-benefit ratio: the level of risk to which the patient is exposed must be proportionate to the benefit derived from the exercise. Medical practitioners must assess and determine whether a plausible tradeoff between the two exists.
An essential requirement for ethical clinical testing is that investigators be well trained and familiar with the applicable code of conduct. Poorly trained investigators are problematic in two ways. First, they are likely to produce unreliable results that offer no scientific value. Second, they are more likely to violate the ethical requirements underlying the research. It is therefore mandatory that investigators be adequately trained before any procedure commences (Silverman, 2007).
"Training requirements and risk-benefit considerations"
"Strengths and weaknesses of the reviewed article"
Silverman, H. (2007). Ethical issues during the conduct of clinical trials. Proceedings of the American Thoracic Society, 4(2), 180–184.
You’re 64% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.